A mathematical model for HIV and hepatitis C co-infection and its assessment from a statistical perspective

Epidemics

Volumn 5, Issue 1, 2013, Pages 56-66

  Castro Sanchez, Amparo Yovanna ^a   Aerts, Marc ^a   Shkedy, Ziv ^a   Vickerman, Peter ^b,c   Faggiano, Fabrizio ^d   Salamina, Guiseppe ^e   Hens, Niel ^a,f  

^a HASSELT UNIVERSITY   (Belgium)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^e Local Health Unit   (Italy)

^f UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

HCV HIV; Inject drug users; Joint deterministic model; Maximum likelihood; Model uncertainty

Indexed keywords

ARTICLE; BOOTSTRAPPING; CONTROLLED STUDY; DRUG USE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL MODEL; MIXED INFECTION; PREVALENCE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROBABILITY; STATISTICAL PARAMETERS; STATISTICAL SIGNIFICANCE; UNCERTAINTY;

COINFECTION; COMPUTER SIMULATION; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; ITALY; LIVER CIRRHOSIS; LIVER NEOPLASMS; MODELS, THEORETICAL; NEEDLE SHARING; PREVALENCE; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84874400775     PISSN: 17554365     EISSN: 18780067     Source Type: Journal    
DOI: 10.1016/j.epidem.2013.01.002     Document Type: Article

References (56)

1. Akaike H. A new look at the statistical model identification. IEEE Transactions on Automatic Control 1974, 19:716-723.
2. Amaratunga D., Cabrera J. Mining data to find subsets of high activity. Journal of Statistical Planning and Inference 2004, 122:23-41.
3. Baggaley R., Boily M., White R., Alary M. Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis. AIDS 2006, 20:805.
4. Bargagli A., Faggiano F., Amato L., Salamina G., Davoli M., Mathis F., Cuomo L., Schifano P., Burroni P., Perucci C. VEdeTTE, a longitudinal study on effectiveness of treatments for heroin addiction in Italy: study protocol and characteristics of study population. Substance Use & Misuse 2006, 41:1861-1879.
5. Bilcke J., Beutels P., Brisson M., Jit M. Accounting for methodological, structural, and parameter uncertainty in decision-analytic models. Medical Decision Making 2011, 31:675-692.
6. Blower S., Dowlatabadi H. Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model, as an example. International Statistical Review/Revue Internationale de Statistique 1994, 229-243.
7. Bouhnik A., Carrieri M., Rey D., Spire B., Gastaut J., Gallais H., Obadia Y., et al. Drug injection cessation among HIV-infected injecting drug users. Addictive Behaviors 2004, 29:1189-1197.
8. Camoni L. Linfezione da HIV e le epatiti B e C nella popolazione tossicodipendente: i dati del Centro Operativo AIDS 2011, (accessed September 18, 2012). http://www.politicheantidroga.it/media/449962/dati_coa_camoni.pdf.
9. Castro-Sanchez A., Shkedy Z., Hens N., Aerts M., Geskus R., Prins M., Wiessing L., Kretzschmar M. Estimating the force of infection for HCV in injecting drug users using interval-censored data. Epidemiology and Infection 2012, 140:1064-1074.
10. Davison A., Hinkley D. Bootstrap Methods and Their Application 1997, vol. 1. Cambridge University Press.
11. Davoli M., Perucci C., Abeni D., Arcà M., Brancato G., Forastiere F., Montiroli P., Zampieri F. HIV risk-related behaviors among injection drug users in Rome: differences between 1990 and 1992. American Journal of Public Health 1995, 85:829-832.
12. Davoli M., Bargagli A., Perucci C., Schifano P., Belleudi V., Hickman M., Salamina G., Diecidue R., Vigna-Taglianti F., Faggiano F. Risk of fatal overdose during and after specialist drug treatment: the Vedette study, a national multi-site prospective cohort study. Addiction 2007, 102:1954-1959.
13. De Carli G., Puro V., Ippolito G., Studio I., et al. Risk of hepatitis C virus transmission following percutaneous exposure in healthcare workers. Infection 2003, 31:22.
14. de Vos A., van der Helm J., Prins M., Kretzschmar M. Determinants of persistent spread of HIV in HCV-infected populations of injecting drug users. Epidemics 2012, 4:57-67.
15. Del Fava E., Shkedy Z., Hens N., Aerts M., Suligoi B., Camoni L., Vallejo F., Wiessing L., Kretzschmar M. Joint modeling of HCV and HIV co-infection among injecting drug users in Italy and Spain using individual cross-sectional data. Statistical Communications in Infectious Diseases 2011, 3:3.
16. Deuffic-Burban S., Wong J., Valleron A., Costagliola D., Delfraissy J., Poynard T. Comparing the public health burden of chronic hepatitis C and HIV infection in France. Journal of Hepatology 2004, 40:319-326.
17. Doherty M., Garfein R., Monterroso E., Brown D., Vlahov D. Correlates of HIV infection among young adult short-term injection drug users. AIDS 2000, 14:717-726.
18. EMCDDA, European Monitoring Centre for Drugs and Drug Addiction EMCDDA Statistical Bulletin 2012 2012, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, (accessed December 6, 2012). http://www.emcdda.europa.eu/stats12.
19. Galai N., Safaeian M., Vlahov D., Bolotin A., Celentano D. Longitudinal patterns of drug injection behavior in the ALIVE Study cohort, 1988-2000: description and determinants. American Journal of Epidemiology 2003, 158:695.
20. Garcia de la Hera M., Ferreros I., del Amo J., de Olalla P., Hoyos S., Muga R., del Romero J., Guerrero R., Hernández-Aguado I. Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting dug users from 1986 to 2001. Journal of Epidemiology and Community Health 2004, 58:944-950.
21. Garnett G., Anderson R. Balancing sexual partnership in an age and activity stratified model of HIV transmission in heterosexual populations. Mathematical Medicine and Biology 1994, 11:161-192.
22. Garnett G., Cousens S., Hallett T., Steketee R., Walker N. Mathematical models in the evaluation of health programmes. Lancet 2011, 378:515-525.
23. Hagan H., Pouget E., Des Jarlais D. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. Journal of Infectious Diseases 2011, 204:74-83.
24. Hoare A., DG R., DP W. Sampling and sensitivity analyses tools (SaSAT) for computational modelling. Theoritical Biology and Medical Modelling 2008, 5.
25. Hutchinson S., Bird S., Taylor A., Goldberg D. Modelling the spread of hepatitis C virus infection among injecting drug users in Glasgow: implications for prevention. International Journal of Drug Policy 2006, 17:211-221.
26. Hutchinson S., Roy K., Wadd S., Bird S., Taylor A., Anderson E., Shaw L., Codere G., Goldberg D. Hepatitis C virus infection in Scotland: epidemiological review and public health challenges. Scotish Medical Journal 2006, 51:8-15.
27. Jarrin I., Geskus R., Bhaskaran K., Prins M., Perez-Hoyos S., Muga R., Hernández-Aguado I., Meyer L., Porter K., Amo J. Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. American Journal of Epidemiology 2008, 168:532.
28. Jit M., Brisson M. Modelling the epidemiology of infectious diseases for decision analysis: a primer. Pharmacoeconomics 2011, 29:371-386.
29. Kapadia F., Vlahov D., Des Jarlais D., Strathdee S., Ouellet L., Kerndt P., Williams I., Garfein R., et al. Does bleach disinfection of syringes protect against hepatitis C infection among young adult injection drug users?. Epidemiology 2002, 13:738-741.
30. Kretzschmar M., Wiessing L. Modelling the transmission of hepatitis C in injecting drug users. Hepatitis C and Injecting Drug Use: Impact, Costs and Policy Options 2004, 143-159. OOPEC. J. Jager, W. Limburg, M. Kretzschmar (Eds.).
31. Micallef J.M., Kaldor J.M., Dore G.J. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. Journal of Viral Hepatitis 2006, 13:34-41.
32. Nelson P., Mathers B., Cowie B., Hagan H., Des Jarlais D., Horyniak D., Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011, 571-583.
33. Okas C., Roche S., Kürzinger M., Riche B., Bricout H., Derrough T., Simondon F., Ecochard R. Methodology of the sensitivity analysis used for modeling an infectious disease. Vaccine 2010, 28:8132-8140.
34. Reshef D., Reshef Y., Finucane H., Grossman S., McVean G., Turnbaugh P., Lander E., Mitzenmacher M., Sabeti P. Detecting novel associations in large data sets. Science 2011, 334:1518-1524.
35. Rockstroh J.K., Spengler U. HIV and hepatitis C virus co-infection. Lancet Infectious Diseases 2004, 4:437-444.
36. Sabbatini A., Carulli B., Villa M., Corrêa Leite M., Nicolosi A., et al. Recent trends in the HIV epidemic among injecting drug users in Northern Italy, 1993-1999. AIDS 2001, 15:2181.
37. Salamina G., Diecidue R., Vigna-Taglianti F., Jarre P., Schifano P., Bargagli A., Davoli M., Amato L., Perucci C., Faggiano F. Effectiveness of therapies for heroin addiction in retaining patients in treatment: results from the Vedette study. Substance Use and Misuse 2010, 45:2076-2092.
38. Serraino D., Zucchetto A., Suligoi B., Bruzzone S., Camoni L., Boros S., Paoli A., Maso L., Franceschi S., Rezza G. Survival after AIDS diagnosis in Italy, 1999-2006: a population-based study. JAIDS 2009, 52:99.
39. Steensma C., Boivin J., Blais L., Roy é. Cessation of injecting drug use among street-based youth. Journal of Urban Health 2005, 82:622-637.
40. Stein M. Large sample properties of simulations using Latin hypercube sampling. Technometrics 1987, 143-151.
41. Suligoi B., Magliochetti N., Nicoletti G., Pezzotti P., Rezza G. Trends in HIV prevalence among drug-users attending public drug-treatment centres in Italy: 1990-2000. Journal of Medical Virology 2004, 73:1-6.
42. Sutton A., Gay N., Edmunds W., Hope V., Gill O., Hickman M. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales. BMC Infectious Diseases 2006, 6:93.
43. Sutton A., Hope V., Mathei C., Mravcik V., Sebakova H., Vallejo F., Suligoi B., Brugal M., Ncube F., Wiessing L., et al. A comparison between the force of infection estimates for blood-borne viruses in injecting drug user populations across the European Union: a modelling study. Journal of Viral Hepatitis 2008, 15:809-816.
44. Todd J., Glynn J., Marston M., Lutalo T., Biraro S., Mwita W., Suriyanon V., Rangsin R., Nelson K., Sonnenberg P., et al. Time from HIV seroconversion to death: a collaborative analysis of eight studies in six low and middle-income countries before highly active antiretroviral therapy. AIDS 2007, 21:S55.
45. UNAIDS, 2010. Global HIV/AIDS response: progress report 2011. Technical report. Joint United Nations Programme on HIV/AIDS (UNAIDS).
46. Vanni T., Karnon J., Madan J., White R., Edmunds W., Foss A., Legood R. Calibrating models in economic evaluation: a seven-step approach. Pharmacoeconomics 2011, 29:35-49.
47. Vickerman P., Hickman M., Judd A. Modelling the impact on hepatitis C transmission of reducing syringe sharing: London case study. International Journal of Epidemiology 2007, 36:396-405.
48. Vickerman, P., Miners, A., Williams, J., 2008. Assessing the cost-effectiveness of interventions linked to needle and syringe programmes for injecting drug users: an economic modelling report. Technical report. National Institute for Health and Clinical Excellence.
49. Vickerman P., Platt L., Hawkes S. Modelling the transmission of HIV and HCV among injecting drug users in Rawalpindi, a low HCV prevalence setting in Pakistan. Sexually Transmitted Infections 2009, 85:ii23-ii30.
50. Vickerman P., Martin N., Hickman M. Understanding the trends in HIV and hepatitis C prevalence amongst injecting drug users in different settings: implications for intervention impact. Drug and Alcohol Dependence 2011.
51. Wasmuth J.C. Hepatitis C - epidemiology, transmission and natural history. Hepatology - A Clinical Text Book 2010, Flying Publisher, Dusseldorf, Germany. 2nd ed. S. Mauss, T. Berg, J. Rockstroh, C. Sarrazin, H. Wedemeyer (Eds.).
52. White R., Ben S., Kedhar A., Orroth K., Biraro S., Baggaley R., Whitworth J., Korenromp E., Ghani A., Boily M., et al. Quantifying HIV-1 transmission due to contaminated injections. Proceedings of the National Academy of Sciences of United States of America 2007, 104:9794-9799.
53. World Health Organization (WHO) Hepatitis C 2011, (accessed 12 July, 2012). http://www.who.int/mediacentre/factsheets/fs164/en/.
54. Wiessing L., Klempova D., Hedrich D., Montanari L., Gyarmathy V. Injecting drug use in Europe: stable or declining. Euro Surveillance: European Communicable Disease Bulletin 2010, 15.
55. Wood S. Generalized Additive Models: An Introduction With R 2006, CRC Press, Boca Ratón, Florida.
56. Yazdanpanah Y., De Carli G., Migueres B., Lot F., Campins M., Colombo C., Thomas T., Deuffic-Burban S., Prevot M., Domart M., et al. Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study. Clinical Infectious Diseases 2005, 41:1423.